MTD
Price
$1631.69
Change
+$5.96 (+0.37%)
Updated
Oct 20, 01:53 PM (EDT)
Capitalization
32.57B
16 days until earnings call
Intraday BUY SELL Signals
SMTI
Price
$33.30
Change
+$0.16 (+0.48%)
Updated
Oct 20, 02:48 PM (EDT)
Capitalization
304.49M
27 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MTD vs SMTI

MTD vs SMTI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MTD vs. SMTI commentary
Oct 20, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MTD is a StrongBuy and SMTI is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MTD with price predictions
Oct 19, 2026

Momentum Indicator for MTD turns positive, indicating new upward trend

MTD saw its Momentum Indicator move above the 0 level on September 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned positive. In 53 of the 82 cases, the stock moved higher in the following days. The odds of a move higher are at 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for MTD just turned positive on September 17, 2026. Looking at past instances where MTD's MACD turned positive, the stock continued to rise in 31 of 48 cases over the following month. The odds of a continued upward trend are 65%.

MTD moved above its 50-day moving average on September 16, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MTD crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.

Following a +2.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where MTD advanced for three days, in 193 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.

The Aroon Indicator entered an Uptrend today. In 134 of 228 cases where MTD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MTD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.

MTD broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 3 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. MTD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MTD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MTD's P/B Ratio (2540.282) is very high in comparison to the industry average of (63.909). P/E Ratio (36.550) is within average values for comparable stocks, (1.606). Projected Growth (PEG Ratio) (2.869) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.798) is also within normal values, averaging (9.775).

A.I.Advisor
a Summary for SMTI with price predictions
Oct 19, 2026

SMTI's RSI Oscillator is staying in oversold zone for 1 day

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +0.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMTI advanced for three days, in 191 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

SMTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 125 of 191 cases where SMTI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 56 cases where SMTI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.

The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SMTI as a result. In 61 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

SMTI moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SMTI crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. SMTI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: SMTI's P/B Ratio (38.332) is very high in comparison to the industry average of (4.887). P/E Ratio (-8.909) is within average values for comparable stocks, (35.995). Projected Growth (PEG Ratio) (2.050) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (2.777) is also within normal values, averaging (56.074).

The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
MTD vs SMTI: Fundamental Ratings
MTD
SMTI
OUTLOOK RATING
1..100
3863
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
8996
SMR RATING
1..100
399
PRICE GROWTH RATING
1..100
1550
P/E GROWTH RATING
1..100
3297
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SMTI's Valuation (81) in the null industry is in the same range as MTD (99) in the Medical Specialties industry. This means that SMTI’s stock grew similarly to MTD’s over the last 12 months.

MTD's Profit vs Risk Rating (89) in the Medical Specialties industry is in the same range as SMTI (96) in the null industry. This means that MTD’s stock grew similarly to SMTI’s over the last 12 months.

MTD's SMR Rating (3) in the Medical Specialties industry is significantly better than the same rating for SMTI (99) in the null industry. This means that MTD’s stock grew significantly faster than SMTI’s over the last 12 months.

MTD's Price Growth Rating (15) in the Medical Specialties industry is somewhat better than the same rating for SMTI (50) in the null industry. This means that MTD’s stock grew somewhat faster than SMTI’s over the last 12 months.

MTD's P/E Growth Rating (32) in the Medical Specialties industry is somewhat better than the same rating for SMTI (97) in the null industry. This means that MTD’s stock grew somewhat faster than SMTI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MTDSMTI
RSI
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 5 days ago
65%
Bearish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
65%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
61%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
60%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 6 days ago
61%
Bullish Trend 9 days ago
75%
Declines
ODDS (%)
Bearish Trend 20 days ago
66%
Bearish Trend 2 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
78%
Aroon
ODDS (%)
Bullish Trend 2 days ago
59%
Bullish Trend 2 days ago
65%
COMPARISON
Comparison
Oct 20, 2026
Stock price -- (MTD: $1625.73 vs. SMTI: $33.14)
Brand notoriety: MTD and SMTI are both not notable
MTD represents the Medical Specialties, while SMTI is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: MTD: 66% vs. SMTI: 43%
Market capitalization -- MTD: $32.57B vs. SMTI: $304.49M
MTD [@Medical Specialties] is valued at $32.57B. SMTI’s [@Pharmaceuticals: Other] market capitalization is $304.49M. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $153.03B. The average market capitalization across the [@Medical Specialties] industry is $20.73B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MTD’s FA Score shows that 3 FA rating(s) are green while SMTI’s FA Score has 0 green FA rating(s).

  • MTD’s FA Score: 3 green, 2 red.
  • SMTI’s FA Score: 0 green, 5 red.
According to our system of comparison, MTD is a better buy in the long-term than SMTI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MTD’s TA Score shows that 6 TA indicator(s) are bullish while SMTI’s TA Score has 4 bullish TA indicator(s).

  • MTD’s TA Score: 6 bullish, 4 bearish.
  • SMTI’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MTD is a better buy in the short-term than SMTI.

Price Growth

MTD (@Medical Specialties) experienced а +4.01% price change this week, while SMTI (@Pharmaceuticals: Other) price change was -5.72% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -0.07%. For the same industry, the average monthly price growth was -3.97%, and the average quarterly price growth was +45.14%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.91%. For the same industry, the average monthly price growth was -2.49%, and the average quarterly price growth was +7.66%.

Reported Earning Dates

MTD is expected to report earnings on Nov 05, 2026.

SMTI is expected to report earnings on Nov 16, 2026.

Industries' Descriptions

@Medical Specialties (-0.07% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

@Pharmaceuticals: Other (+0.91% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
MTD
Daily Signal:
Gain/Loss:
SMTI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SOXL98.654.98
+5.32%
Direxion Daily Semiconductor Bull 3X ETF (SOXL)
PCLN29.420.15
+0.53%
Pictet Cleaner Planet ETF (PCLN)
NBCR34.260.15
+0.44%
Neuberger Core Equity ETF (NBCR)
JOET45.060.05
+0.11%
Virtus Terranova U.S. Quality Momentum ETF (JOET)
LENS43.88-0.12
-0.27%
Sarmaya Thematic ETF (LENS)